NCT03869632: First in Human Dose Escalation Study of YL-13027 in Subjects With Advanced Stage Solid Tumors

NCT03869632
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Serine-Threonine Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years to 75 Years (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with central nervous system metastasis
https://ClinicalTrials.gov/show/NCT03869632

Comments are closed.

Up ↑